(SHL) Siemens Healthineers - Ratings and Ratios
Imaging Systems, Diagnostic Equipment, Cancer Care Tech, Therapy
SHL EPS (Earnings per Share)
SHL Revenue
Description: SHL Siemens Healthineers
Siemens Healthineers AG is a global healthcare company that develops, manufactures, and sells diagnostic and therapeutic products and services. The company operates through four main segments: Imaging, Diagnostics, Varian, and Advanced Therapies, offering a range of medical equipment and services, including MRI and CT scanners, in-vitro diagnostic products, cancer care technologies, and image-guided minimally invasive treatments.
Key Performance Indicators (KPIs) for Siemens Healthineers AG include revenue growth, which has been driven by the increasing demand for healthcare services and the companys expanding portfolio of innovative products. The companys return on equity (RoE) is 11.16%, indicating a relatively stable return on shareholder investment. Additionally, the companys forward price-to-earnings ratio (P/E Forward) is 18.38, suggesting that the stock may be undervalued relative to its expected earnings growth.
The companys diversified product portfolio and global presence provide a solid foundation for long-term growth. Siemens Healthineers AG has a strong presence in the healthcare equipment industry, with a market capitalization of 52.634 billion EUR. The companys commitment to innovation and customer service is reflected in its comprehensive range of technical customer services, including maintenance, repair, and training.
From a valuation perspective, Siemens Healthineers AGs price-to-earnings ratio (P/E) is 25.23, which is relatively high compared to some of its peers. However, this may be justified by the companys strong brand reputation, diversified product portfolio, and growth prospects. Further analysis of the companys financial statements and industry trends is necessary to determine the stocks potential for long-term growth.
Additional Sources for SHL Stock
SHL Stock Overview
| Market Cap in USD | 62,202m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
SHL Stock Ratings
| Growth Rating | 9.07 |
| Fundamental | 42.7 |
| Dividend Rating | 53.0 |
| Rel. Strength | 8.44 |
| Analysts | - |
| Fair Price Momentum | 41.59 EUR |
| Fair Price DCF | 26.32 EUR |
SHL Dividends
| Dividend Yield 12m | 1.97% |
| Yield on Cost 5y | 2.59% |
| Annual Growth 5y | 3.50% |
| Payout Consistency | 98.6% |
| Payout Ratio | 44.4% |
SHL Growth Ratios
| Growth Correlation 3m | -21.3% |
| Growth Correlation 12m | -45.4% |
| Growth Correlation 5y | 32.2% |
| CAGR 5y | 4.72% |
| CAGR/Max DD 5y | 0.13 |
| Sharpe Ratio 12m | -0.28 |
| Alpha | -17.78 |
| Beta | 0.880 |
| Volatility | 23.64% |
| Current Volume | 1280k |
| Average Volume 20d | 786.3k |
| Stop Loss | 45 (-3.1%) |
As of August 02, 2025, the stock is trading at EUR 46.43 with a total of 1,280,023 shares traded.
Over the past week, the price has changed by -3.21%, over one month by -1.04%, over three months by -3.29% and over the past year by -4.33%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Siemens Healthineers (XETRA:SHL) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 42.68 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SHL is around 41.59 EUR . This means that SHL is currently overvalued and has a potential downside of -10.42%.
Siemens Healthineers has no consensus analysts rating.
According to our own proprietary Forecast Model, SHL Siemens Healthineers will be worth about 47.8 in August 2026. The stock is currently trading at 46.43. This means that the stock has a potential upside of +2.95%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 59.7 | 28.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 47.8 | 3% |